241 related articles for article (PubMed ID: 17214673)
1. Interferon Alfa-2b or not 2b? Significant differences exist in the decision-making process between melanoma patients who accept or decline high-dose adjuvant interferon Alfa-2b treatment.
Bramlette TB; Lawson DH; Washington CV; Veledar E; Johns BR; Brisman SF; Abramova L; Chen SC
Dermatol Surg; 2007 Jan; 33(1):11-6. PubMed ID: 17214673
[TBL] [Abstract][Full Text] [Related]
2. Final Results of the Sunbelt Melanoma Trial: A Multi-Institutional Prospective Randomized Phase III Study Evaluating the Role of Adjuvant High-Dose Interferon Alfa-2b and Completion Lymph Node Dissection for Patients Staged by Sentinel Lymph Node Biopsy.
McMasters KM; Egger ME; Edwards MJ; Ross MI; Reintgen DS; Noyes RD; Martin RC; Goydos JS; Beitsch PD; Urist MM; Ariyan S; Sussman JJ; Davidson BS; Gershenwald JE; Hagendoorn LJ; Stromberg AJ; Scoggins CR
J Clin Oncol; 2016 Apr; 34(10):1079-86. PubMed ID: 26858331
[TBL] [Abstract][Full Text] [Related]
3. Developing indications for the use of sentinel lymph node biopsy and adjuvant high-dose interferon alfa-2b in melanoma.
Dubois RW; Swetter SM; Atkins M; McMasters K; Halbert R; Miller SJ; Shiell R; Kirkwood J
Arch Dermatol; 2001 Sep; 137(9):1217-24. PubMed ID: 11559220
[TBL] [Abstract][Full Text] [Related]
4. The adjuvant treatment of malignant melanoma.
Reintgen D; Kirkwood J
J Fla Med Assoc; 1997 Mar; 84(3):147-52. PubMed ID: 9143164
[TBL] [Abstract][Full Text] [Related]
5. Long term follow up of the EORTC 18952 trial of adjuvant therapy in resected stage IIB-III cutaneous melanoma patients comparing intermediate doses of interferon-alpha-2b (IFN) with observation: Ulceration of primary is key determinant for IFN-sensitivity.
Eggermont AM; Suciu S; Rutkowski P; Kruit WH; Punt CJ; Dummer R; Salès F; Keilholz U; de Schaetzen G; Testori A;
Eur J Cancer; 2016 Mar; 55():111-21. PubMed ID: 26790144
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant therapy with pegylated interferon alfa-2b (36 months) versus low-dose interferon alfa-2b (18 months) in melanoma patients without macrometastatic nodes: an open-label, randomised, phase 3 European Association for Dermato-Oncology (EADO) study.
Grob JJ; Jouary T; Dréno B; Asselineau J; Gutzmer R; Hauschild A; Leccia MT; Landthaler M; Garbe C; Sassolas B; Herbst RA; Guillot B; Chene G; Pehamberger H
Eur J Cancer; 2013 Jan; 49(1):166-74. PubMed ID: 22975216
[TBL] [Abstract][Full Text] [Related]
7. The benefit of a sentinel lymph node biopsy and adjuvant therapy in thick (>4 mm) melanoma: multicenter, retrospective study of 291 Japanese patients.
Fujisawa Y; Otsuka F;
Melanoma Res; 2012 Oct; 22(5):362-7. PubMed ID: 22713797
[TBL] [Abstract][Full Text] [Related]
8. Preferences of German melanoma patients for interferon (IFN) α-2b toxicities (the DeCOG "GERMELATOX survey") versus melanoma recurrence to quantify patients' relative values for adjuvant therapy.
Kaehler KC; Blome C; Forschner A; Gutzmer R; Haalck T; Heinzerling L; Kornek T; Livingstone E; Loquai C; Maul LV; Lang BM; Schadendorf D; Stade B; Terheyden P; Utikal J; Wagner T; Hauschild A; Garbe C; Augustin M
Medicine (Baltimore); 2016 Nov; 95(46):e5375. PubMed ID: 27861370
[TBL] [Abstract][Full Text] [Related]
9. Patient preferences for adjuvant interferon alfa-2b treatment.
Kilbridge KL; Weeks JC; Sober AJ; Haluska FG; Slingluff CL; Atkins MB; Sock DE; Kirkwood JM; Nease RF
J Clin Oncol; 2001 Feb; 19(3):812-23. PubMed ID: 11157035
[TBL] [Abstract][Full Text] [Related]
10. Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial.
Eggermont AM; Suciu S; MacKie R; Ruka W; Testori A; Kruit W; Punt CJ; Delauney M; Sales F; Groenewegen G; Ruiter DJ; Jagiello I; Stoitchkov K; Keilholz U; Lienard D;
Lancet; 2005 Oct; 366(9492):1189-96. PubMed ID: 16198768
[TBL] [Abstract][Full Text] [Related]
11. Prospective randomized multicenter adjuvant dermatologic cooperative oncology group trial of low-dose interferon alfa-2b with or without a modified high-dose interferon alfa-2b induction phase in patients with lymph node-negative melanoma.
Hauschild A; Weichenthal M; Rass K; Linse R; Ulrich J; Stadler R; Volkenandt M; Grabbe S; Proske U; Schadendorf D; Brockmeyer N; Vogt T; Rompel R; Kaufmann R; Kaatz M; Näher H; Mohr P; Eigentler T; Livingstone E; Garbe C
J Clin Oncol; 2009 Jul; 27(21):3496-502. PubMed ID: 19433681
[TBL] [Abstract][Full Text] [Related]
12. Recent advances in the care of the patient with malignant melanoma.
Reintgen D; Balch CM; Kirkwood J; Ross M
Ann Surg; 1997 Jan; 225(1):1-14. PubMed ID: 8998115
[TBL] [Abstract][Full Text] [Related]
13. Ulceration as a predictive marker for response to adjuvant interferon therapy in melanoma.
McMasters KM; Edwards MJ; Ross MI; Reintgen DS; Martin RC; Urist MM; Noyes RD; Sussman JJ; Stromberg AJ; Scoggins CR
Ann Surg; 2010 Sep; 252(3):460-5; discussion 465-6. PubMed ID: 20739846
[TBL] [Abstract][Full Text] [Related]
14. The feasibility of adjuvant interferon alpha-2b in children with high-risk melanoma.
Navid F; Furman WL; Fleming M; Rao BN; Kovach S; Billups CA; Cain AM; Amonette R; Jenkins JJ; Pappo AS
Cancer; 2005 Feb; 103(4):780-7. PubMed ID: 15660397
[TBL] [Abstract][Full Text] [Related]
15. Potential drug-drug interaction between interferon alfa-2b and gemfibrozil in a patient with malignant melanoma.
Wong SF; Jakowatz JG; Taheri R
Clin Ther; 2005 Dec; 27(12):1942-8. PubMed ID: 16507380
[TBL] [Abstract][Full Text] [Related]
16. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.
Kirkwood JM; Strawderman MH; Ernstoff MS; Smith TJ; Borden EC; Blum RH
J Clin Oncol; 1996 Jan; 14(1):7-17. PubMed ID: 8558223
[TBL] [Abstract][Full Text] [Related]
17. Quality-of-life evaluation in an interferon therapy after radical surgery in cutaneous melanoma patients.
Rataj D; Jankowiak B; Krajewska-Kułak E; Van Damme-Ostapowicz K; Nowecki ZI; Rutkowski P; Niczyporuk W
Cancer Nurs; 2005; 28(3):172-8. PubMed ID: 15915059
[TBL] [Abstract][Full Text] [Related]
18. Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon Alfa-2b compared with high-dose interferon Alfa-2b for Resected stage III cutaneous melanoma.
Mitchell MS; Abrams J; Thompson JA; Kashani-Sabet M; DeConti RC; Hwu WJ; Atkins MB; Whitman E; Ernstoff MS; Haluska FG; Jakowatz JG; Das Gupta TK; Richards JM; Samlowski WE; Costanzi JJ; Aronson FR; Deisseroth AB; Dudek AZ; Jones VE
J Clin Oncol; 2007 May; 25(15):2078-85. PubMed ID: 17513813
[TBL] [Abstract][Full Text] [Related]
19. Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group study.
Cole BF; Gelber RD; Kirkwood JM; Goldhirsch A; Barylak E; Borden E
J Clin Oncol; 1996 Oct; 14(10):2666-73. PubMed ID: 8874325
[TBL] [Abstract][Full Text] [Related]
20. Intermittent High-Dose Intravenous Interferon Alfa-2b for Adjuvant Treatment of Stage III Melanoma: Final Analysis of a Randomized Phase III Dermatologic Cooperative Oncology Group Trial.
Mohr P; Hauschild A; Trefzer U; Enk A; Tilgen W; Loquai C; Gogas H; Haalck T; Koller J; Dummer R; Gutzmer R; Brockmeyer N; Hölzle E; Sunderkötter C; Mauch C; Stein A; Schneider LA; Podda M; Göppner D; Schadendorf D; Weichenthal M
J Clin Oncol; 2015 Dec; 33(34):4077-84. PubMed ID: 26503196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]